AFT Pharmaceuticals Ltd.
4.62
NZD
+0.03
(+0.65%)
ISIN
NZAFTE0001S4
Return %
Stock
S&P 500
1Y
52.48
14.20
3Y
35.88
81.12
5Y
12.68
68.34
Capital Structure
NZD
•
in mil. unless spec.Working Capital
NZD
•
in mil. unless spec.Growth Rates
NZD
•
in mil. unless spec.Semi-annual Revenue
NZD
•
in mil. unless spec.Semi-annual Earnings Per Share
NZD
•
in mil. unless spec.Semi-annual Dividends Per Share
NZD
•
in mil. unless spec.Company Description
- CEO
- Hartley Atkinson
- Full Time Employees
- 126
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 129 Hurstmere Road Auckland AU New Zealand 0622
- IPO Date
- Dec 22, 2015
- Website
- aftpharm.com
- Similar Companies
- Business
- AFT Pharmaceuticals Limited is a New Zealand-based pharmaceutical company specializing in the development, manufacturing, and marketing of proprietary pharmaceutical products and consumer healthcare products. The company's core offerings include prescription medicines; over-the-counter (OTC) pharmaceuticals; complementary and wellness products; and specialty pharmaceutical products primarily targeting respiratory, dermatological, gastrointestinal, and musculoskeletal conditions. AFT markets a diverse portfolio of branded and generic medicines, including nasal sprays, eye drops, analgesics, cough and cold remedies, and vitamins and supplements. Founded in 1976 and headquartered in Auckland, New Zealand, AFT Pharmaceuticals operates globally with commercial presence in Australia, New Zealand, the United States, the United Kingdom, and several other international markets. The company serves healthcare professionals, pharmacies, hospitals, and consumers in these regions. In the past 1-2 years, AFT Pharmaceuticals has focused on strategic growth initiatives, including expanding its product pipeline with new launches, forming strategic partnerships to enhance market reach, and acquiring complementary product lines to diversify its portfolio. Notably, the company has strengthened its respiratory and dermatology segments, launched innovative consumer health products, and extended its distribution capabilities in key international markets. These developments reflect AFT's commitment to broadening its therapeutic offerings and enhancing its global footprint in the pharmaceutical sector. Overall, AFT Pharmaceuticals Limited positions itself as a specialist healthcare company delivering clinically effective medicines and wellness products with a growing international presence. Its blend of proprietary innovations and established brands supports sustained growth within the pharmaceutical and consumer healthcare industries.
Company News
Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market